This Swedish nationwide longitudinal research included 192 sufferers who underwent esophagectomy for most cancers. The publicity was dispositional optimism measured by the Life Orientation Check-Revised (LOT-R) at 1 yr post-surgery. Sufferers have been categorized into 4 subgroups (very low, reasonably low, reasonably excessive, and really excessive dispositional optimism) primarily based on the quartile of the LOT-R sum rating. The result was HRQL assessed by the European Group for Analysis and Therapy of Most cancers High quality of Life Questionnaire-Core 30 and High quality of Life Questionnaire-Esophago-Gastric module 25 at 1, 1.5, and a couple of years post-surgery.
Linear mixed-effects fashions, adjusted for potential confounders, have been used to look at the imply rating distinction (MSD) with 95% confidence interval of HRQL among the many 4 affected person subgroups. Sufferers with very excessive dispositional optimism reported clinically relevantly higher world high quality of life, emotional perform, and social perform (MSD vary 10-16) and fewer extreme signs in ache, dyspnea, diarrhea, consuming problem, anxiousness, dry mouth, bother with style, fear about weight reduction, and self-doubt about physique picture (MSD vary – 9 to – 22) than sufferers with decrease dispositional optimism.
Sufferers with reasonably excessive dispositional optimism reported clinically and statistically considerably higher world high quality of life (MSD 10) and fewer extreme diarrhea (MSD – 9) than sufferers with decrease dispositional optimism. Adjusted MSDs have been fixed over the three time factors in all features aside from consuming problem. Subsequently, the DF-based SA successfully solves the issue of fabric shedding and growing older, thus enhancing the soundness and injury threshold of the fiber laser.
COVID-19: unbalanced administration of occupational risks-case of the evaluation of the chemical threat associated to the usage of disinfectants within the dairy business in Morocco
Moroccan employers have a robust duty for the security and well being of their staff within the office and for shielding them from the chance of COVID-19 and any occupational hazards, as required by Moroccan legislation. As a consequence, industries, together with the agri-food sector, have put in place preventive measures to cope with this pandemic on a number of fronts, together with the usage of hydroalcoholic merchandise and bleach for private and floor disinfection.
These disinfection actions might remove or scale back the chance of coronavirus an infection, however the elevated use of those merchandise by staff may result in critical well being issues and improve the occupational chemical threat within the occasion of uncontrolled publicity. With the intention to analyze this threat within the dairy business in Morocco, we now have launched a qualitative and quantitative research to establish and assess the severity of chemical threat to which its staff are uncovered.
This includes an evaluation of the security information sheets [MSDS] of the disinfectants used and a well being and security survey of the customers of those merchandise, significantly for hand disinfection. This evaluation confirmed that this chemical threat is omnipresent and prevention measures are partially adopted. Certainly, the strengthening of well being security measures to fight COVID-19 has considerably elevated this threat, leading to a outstanding imbalance within the evaluation and administration of occupational dangers on this business.
That is the usage of the Danger Evaluation-Important Management Factors (HACCP)-Instrument for a First Danger Evaluation by Exercise Evaluation (OPERA) method, which we developed and proposed in a earlier research, for a simplified administration of chemical threat within the meals business, particularly in small- and medium-sized enterprises. These outcomes have led us to suggest corrective and preventive measures towards this threat to events and to undertake an built-in administration of meals and occupational well being dangers in a single system.
Monitoring-based deep studying methodology for temporomandibular joint segmentation
The form, measurement, and floor info regarding the glenoid fossae and condyles in temporomandibular joints (TMJ) are important for diagnosing and treating. Sufferers with TMJ illness usually have floor abrasion which can trigger fuzzy edges in computed tomography (CT) imaging, particularly for low-dose CT, making TMJ segmentation harder. On this paper, an computerized segmentation algorithm primarily based on deep studying and post-processing was launched.
First, U-Internet was used to divide photos into three classes: glenoid fossae, condyles, and background. For structural fractures in these divided photos, the inner pressure constraint of a snake mannequin was used to replenish the integrity of the fracture boundary in a post-processing operation, and the preliminary boundary of the snake was obtained primarily based on the idea of the monitoring idea. A complete of 206 instances of low-dose CT have been used to confirm the effectiveness of the algorithm, and such indicators because the Cube coefficient (DC) and imply floor distance (MSD) have been used to judge the settlement between experimental outcomes and the gold normal.
) Anti-CD19-ScFv-4-1BB-CD3ζ (Bsd) |
|
LVP1441 |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: Anti-CD19 CAR Lentivirus with human 4-1BB (CD137) stimulatory domain, containing Blasticidin selection |
) Anti-CD19-ScFv-4-1BB-CD3ζ (Puro) |
|
LVP1440 |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: Anti-CD19 CAR Lentivirus with human 4-1BB (CD137) stimulatory domain, containing Puromycin selection. |
) Anti-CD19-ScFv-4-1BB-CD3ζ (no marker) |
|
LVP1444 |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: Anti-CD19 CAR Lentivirus with human 4-1BB (CD137) stimulatory domain, do not contain any selection marker. |
) Anti-CD19-ScFv-4-1BB-CD3ζ (GFP-Puro) |
|
LVP1442 |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: Anti-CD19 CAR Lentivirus with human 4-1BB (CD137) stimulatory domain, containing GFP-Puromycin dual selection. |
) Anti-CD19-ScFv-4-1BB-CD3ζ (RFP-Puro) |
|
LVP1443 |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: Anti-CD19 CAR Lentivirus with human 4-1BB (CD137) stimulatory domain, containing RFP-Puromycin dual selection. |
) CAR negative control: Anti-CD19-ScFv-4-1BB (Puro) |
|
CAR-ctr2 |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 276.5 |
|
Description: Anti-CD19 (4-1BB) control lentivirus without activation domain, containing Puromycin selection |
 Lentivirus) Anti-CD19_CD20-ScFv- CD28-CD3ζ (Puro) Lentivirus |
|
LVP1645 |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 553 |
|
Description: Bispecific Anti-CD19/CD20 CAR Lentivirus with human CD28 stimulatory domain, containing puromycin antibiotic selection |
 Lentivirus) Anti-CD19_CD20-ScFv- CD28-CD3ζ (No Select) Lentivirus |
|
LVP1644 |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 553 |
|
Description: Bispecific Anti-CD19/CD20 CAR Lentivirus with human CD28 stimulatory domain, do not contain antibiotic selection |
 Lentivirus) Anti-CD19_CD20-ScFv- CD28-CD3ζ (GFP-Puro) Lentivirus |
|
LVP1646 |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 553 |
|
Description: Bispecific Anti-CD19/CD20 CAR Lentivirus with human CD28 stimulatory domain, containing GFP-Puromycin dual selection |
 Reporter Jurkat Cell Line (CD19 SCFV-CD28-4-1BB-CD3ζ)) Anti-CD19 CAR / NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28-4-1BB-CD3ζ) |
|
79853 |
BPS Bioscience |
2 vials |
EUR 10340 |
|
Description: Anti-CD19 CAR/NFAT-luciferase reporter Jurkat cell line is a double stable cell line expressing anti-CD19 CAR and NFAT-luciferase reporter. It is made from the anti-CD19 CAR lentivirus (BPS Bioscience #79851). The reporter cell line has been validated for anti CD19-CAR expression by FACS, and for luciferase reporter activation stimulated by target cells including CD19/CHO recombinant cell line can be used for primary screening and functional validation of anti-CD19 CAR construct and lentivirus before testing in primary T cells.
Anti-CD19 CAR consists of anti-CD19 scFv linked to 3rd generation CAR (Chimeric Antigen Receptor) containing CD28, 4-1BB co-stimulatory domains, and CD3ζ signaling domain.
|
 Lentivirus) Anti-CD19_CD20-ScFv-4-1BB-CD3ζ (Puro) Lentivirus |
|
LVP1642 |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 553 |
|
Description: Bispecific Anti-CD19/CD20 CAR Lentivirus with human 4-1BB (CD137) stimulatory domain, containing puromycin antibiotic selection |
 Lentivirus) Anti-CD19_CD20-ScFv-4-1BB-CD3ζ (No Select) Lentivirus |
|
LVP1641 |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 553 |
|
Description: Bispecific Anti-CD19/CD20 CAR Lentivirus with human 4-1BB (CD137) stimulatory domain, do not contain antibiotic selection |
 Lentivirus) Anti-CD19_CD20-ScFv-4-1BB-CD3ζ (GFP-Puro) Lentivirus |
|
LVP1643 |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 553 |
|
Description: Bispecific Anti-CD19/CD20 CAR Lentivirus with human 4-1BB (CD137) stimulatory domain, containing GFP-Puromycin dual selection |
) Anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3ζ) |
|
78600 |
BPS Bioscience |
50 µl |
EUR 1150 |
|
Description: The anti-CD19 CAR lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. These viruses constitutively express the ScFv portion of anti-CD19 (clone FMC63) linked to 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge, 4-1BB, and CD3ζ signaling domains. |
 Anti-CD28 Antibody [CD28.2], PE-25Tests |
|
QAB37-PE-25Tests |
EnQuireBio |
25Tests |
EUR 169.2 |
 Anti-CD28 Antibody [CD28.2], APC-25Tests |
|
QAB37-APC-25Tests |
EnQuireBio |
25Tests |
EUR 188.4 |
 Anti-CD28 Antibody [CD28.2], PE-100Tests |
|
QAB37-PE-100Tests |
EnQuireBio |
100Tests |
EUR 270 |
 Anti-CD28 Antibody [CD28.2], APC-100Tests |
|
QAB37-APC-100Tests |
EnQuireBio |
100Tests |
EUR 310.8 |
 Anti-CD28 Antibody [CD28.2], FITC-25Tests |
|
QAB37-F-25Tests |
EnQuireBio |
25Tests |
EUR 157.2 |
 Anti-CD28 Antibody [CD28.2], FITC-100Tests |
|
QAB37-F-100Tests |
EnQuireBio |
100Tests |
EUR 240 |
) Anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3ζ; SIN Vector) |
|
78601 |
BPS Bioscience |
50 µl |
EUR 1150 |
|
Description: The anti-CD19 CAR lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses transduce the ScFv portion of anti-CD19 (clone FMC63) linked to 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, 4-1BB and CD3ζ signaling domains .Note: This product transduces the same construct as the anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3ζ) (BPS Bioscience #78600), but differs in key aspects:78601 is constructed with a SIN lentivector while 78600 is not. 78601 does not contain an antibiotic for selection while 78600 contains a puromycin selection so the transduced cells can be selected with puromycin. |
 Anti-CD28 Antibody [CD28.2], Qfluor 630-100ug |
|
QAB37-QF630-100ug |
EnQuireBio |
100ug |
EUR 259.2 |
 Anti-CD28 Antibody [CD28.2], Unconjugated-100ug |
|
QAB37-100ug |
EnQuireBio |
100ug |
EUR 169.2 |
 Anti-CD28 Antibody [CD28.2], PE-Cy7-25Tests |
|
QAB37-PE7-25Tests |
EnQuireBio |
25Tests |
EUR 199.2 |
 Anti-CD28 Antibody [CD28.2], PerCP-Cy5.5-100Tests |
|
QAB37-PCP55-100Tests |
EnQuireBio |
100Tests |
EUR 381.6 |
 Anti-CD28 Antibody [CD28.2], PerCP-Cy5.5-25Tests |
|
QAB37-PCP55-25Tests |
EnQuireBio |
25Tests |
EUR 229.2 |
 Anti-CD28 Antibody [CD28.2], PE-Cy7-100Tests |
|
QAB37-PE7-100Tests |
EnQuireBio |
100Tests |
EUR 340.8 |
 Anti-CD3/CD28 stimulus for human PBMC |
|
CT372 |
U-CyTech |
50 tests |
EUR 141.6 |
) CAR negative control: CD28-CD3ζ (Puro) |
|
CAR-ctr3 |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 276.5 |
|
Description: CAR-T CD28 control lentivirus without targeting domain, containing Puromycin selection |
 Lentivirus) Anti-BCMA-ScFv- CD28-CD3ζ (Puro) Lentivirus |
|
LVP1651 |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 553 |
|
Description: Anti-BCMA CAR Lentivirus with human CD28 stimulatory domain, containing Puromycin antibiotic selection. |
 Lentivirus) Anti-h CD22-ScFv- CD28-CD3ζ (Puro) Lentivirus |
|
LVP1663 |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 553 |
|
Description: Anti-h CD22 CAR Lentivirus with human CD28 stimulatory domain, containing Puromycin antibiotic selection. |
 Hamster Anti CD28 Antibody |
|
20-abx137056 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
|
 Lentivirus) Anti-h HER2-ScFv- CD28-CD3ζ (Puro) Lentivirus |
|
LVP1657 |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 553 |
|
Description: Anti-h HER2 CAR Lentivirus with human CD28 stimulatory domain, containing Puromycin antibiotic selection. |
 Lentivirus) Anti-h TGFb-ScFv- CD28-CD3ζ (Puro) Lentivirus |
|
LVP1675 |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 553 |
|
Description: Anti-h TGFb CAR Lentivirus with human CD28 stimulatory domain, containing Puromycin antibiotic selection. |
 Lentivirus) Anti-BCMA-ScFv- CD28-CD3ζ (No Select) Lentivirus |
|
LVP1650 |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 553 |
|
Description: Anti-BCMA CAR Lentivirus with human CD28 stimulatory domain, does not contain any antibiotic selection. |
 Lentivirus) Anti-BCMA-ScFv- CD28-CD3ζ (GFP-Puro) Lentivirus |
|
LVP1652 |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 553 |
|
Description: Anti-BCMA CAR Lentivirus with human CD28 stimulatory domain, containing GFP-Puromycin dual selection. |
 Anti- CD28 Monoclonal Antibody |
|
M00065-1 |
BosterBio |
100ug |
EUR 299 |
|
|
|
Description: Boster Bio Anti- CD28 Monoclonal Antibody catalog # M00065-1. Tested in IHC-P applications. This antibody reacts with Mouse. |
 Absolute Mcell™ Anti-CD3/CD28 Antibody Magnetic Particles, 5.5 µm, DMF Filed, Sterile |
|
WHM-AB23-095 |
Creative Diagnostics |
2.5 mg |
EUR 680 |
 Lentivirus) Anti-h CD22-ScFv- CD28-CD3ζ (No Select) Lentivirus |
|
LVP1662 |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 553 |
|
Description: Anti-h CD22 CAR Lentivirus with human CD28 stimulatory domain, does not contain any antibiotic selection. |
 Lentivirus) Anti-h CD22-ScFv- CD28-CD3ζ (GFP-Puro) Lentivirus |
|
LVP1664 |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 553 |
|
Description: Anti-h CD22 CAR Lentivirus with human CD28 stimulatory domain, containing GFP-Puromycin dual selection. |
 Anti-CD28 |
|
E40YR1618 |
EnoGene |
1 mg |
EUR 2960 |
|
Description: Available in various conjugation types. |
 anti-CD28 |
|
YF-PA10780 |
Abfrontier |
50 ug |
EUR 435.6 |
|
Description: Mouse polyclonal to CD28 |
 Hamster Anti CD28 FITC Antibody |
|
20-abx137135 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
|
 Lentivirus) Anti-h HLA-A2-ScFv- CD28-CD3ζ (Puro) Lentivirus |
|
LVP1669 |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 553 |
|
Description: Anti-h HLA-A2 CAR Lentivirus with human CD28 stimulatory domain, containing Puromycin antibiotic selection. |
 Lentivirus) Anti-h HER2-ScFv- CD28-CD3ζ (No Select) Lentivirus |
|
LVP1656 |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 553 |
|
Description: Anti-h HER2 CAR Lentivirus with human CD28 stimulatory domain, does not contain any antibiotic selection. |
 Lentivirus) Anti-h TGFb-ScFv- CD28-CD3ζ (No Select) Lentivirus |
|
LVP1674 |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 553 |
|
Description: Anti-h TGFb CAR Lentivirus with human CD28 stimulatory domain, does not contain any antibiotic selection. |
 Lentivirus) Anti-h HER2-ScFv- CD28-CD3ζ (GFP-Puro) Lentivirus |
|
LVP1658 |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 553 |
|
Description: Anti-h HER2 CAR Lentivirus with human CD28 stimulatory domain, containing GFP-Puromycin dual selection. |
 Lentivirus) Anti-h TGFb-ScFv- CD28-CD3ζ (GFP-Puro) Lentivirus |
|
LVP1676 |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 553 |
|
Description: Anti-h TGFb CAR Lentivirus with human CD28 stimulatory domain, containing GFP-Puromycin dual selection. |
 Reporter Jurkat Cell Line (CD19 SCFV-CD28 transmembrane motif)) Anti-CD19 CAR negative control/ NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28 transmembrane motif) |
|
79854 |
BPS Bioscience |
2 vials |
EUR 1650 |
|
Description: Anti-CD19 CAR negative control/NFAT-luciferase reporter Jurkat cell line is a double stable cell line expressing anti-CD19 CAR negative control and NFAT-luciferase reporter. The anti-CD19 CAR negative control consists of anti-CD19 scFv linked to the CD28 transmembrane motif without any intracellular signaling domains. The reporter cell line has been validated for anti- CD19 expression by FACS, while the stimulation by target cells including CD19/CHO recombinant cell line has not activated the luciferase reporter gene in this cell line. The cell line can be used for the negative control of anti-CD19 CAR/Jurkat-NFAT cell line (BPS Bioscience, #79853)._x000D_ _x000D_ |
 Mouse anti CD28 Monoclonal Antibody |
|
MBS460489-01mg |
MyBiosource |
0.1mg |
EUR 320 |
Mouse anti CD28 Monoclonal Antibody |
|
MBS460489-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1390 |
 Lentivirus) CAR negative control:
CD28-CD3ζ (No Select) Lentivirus |
|
CAR-ctr6 |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 276.5 |
|
Description: CAR (CD28) control lentivirus without targeting domain, does not contain any antibiotic selection |
 Lentivirus) CAR negative control:
CD28-CD3ζ (GFP-Puro) Lentivirus |
|
CAR-ctr8 |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 276.5 |
|
Description: CAR (CD28) control lentivirus without targeting domain, containing GFP-Puromycin dual selection |
 Hamster Anti CD28 Biotinylated Antibody |
|
20-abx137134 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
|
 Anti-CD28 [1C6] |
|
MBS488426-02mg |
MyBiosource |
0.2mg |
EUR 520 |
Anti-CD28 [1C6] |
|
MBS488426-5x02mg |
MyBiosource |
5x0.2mg |
EUR 2160 |
 Anti-CD28 [D665] |
|
MBS488400-02mg |
MyBiosource |
0.2mg |
EUR 520 |
Anti-CD28 [D665] |
|
MBS488400-5x02mg |
MyBiosource |
5x0.2mg |
EUR 2160 |
Anti-CD28 [D665] |
|
MBS488401-02mg |
MyBiosource |
0.2mg |
EUR 520 |
Anti-CD28 [D665] |
|
MBS488401-5x02mg |
MyBiosource |
5x0.2mg |
EUR 2160 |
 Anti-CD28 [JJ316] |
|
MBS488398-02mg |
MyBiosource |
0.2mg |
EUR 520 |
Anti-CD28 [JJ316] |
|
MBS488398-5x02mg |
MyBiosource |
5x0.2mg |
EUR 2160 |
Anti-CD28 [JJ316] |
|
MBS488399-02mg |
MyBiosource |
0.2mg |
EUR 520 |
Anti-CD28 [JJ316] |
|
MBS488399-5x02mg |
MyBiosource |
5x0.2mg |
EUR 2160 |
 Anti-CD28 Antibody |
|
A00065 |
BosterBio |
0.1mg |
EUR 449 |
|
|
|
Description: Boster Bio Anti-CD28 Antibody (Catalog # A00065). Tested in ELISA, WB, IHC, IF applications. This antibody reacts with Human. |
Anti-CD28 Antibody |
|
E38A8582 |
EnoGene |
100ug/100ul |
EUR 225 |
|
Description: Available in various conjugation types. |
Anti-CD28 Antibody |
|
E38A8787 |
EnoGene |
100ug/100ul |
EUR 225 |
|
Description: Available in various conjugation types. |
Anti-CD28 Antibody |
|
ER2001-42 |
HUABIO |
100ul |
EUR 189 |
|
|
|
Description: CD28 (Cluster of Differentiation 28) is one of the proteins expressed on T cells that provide co-stimulatory signals required for T cell activation and survival. T cell stimulation through CD28 in addition to the T-cell receptor (TCR) can provide a potent signal for the production of various interleukins (IL-6 in particular). CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2) proteins. When activated by Toll-like receptor ligands, the CD80 expression is upregulated in antigen-presenting cells (APCs). The CD86 expression on antigen-presenting cells is constitutive (expression is independent of environmental factors). CD28 is the only B7 receptor constitutively expressed on naive T cells. Association of the TCR of a naive T cell with MHC:antigen complex without CD28:B7 interaction results in a T cell that is anergic. |
 Anti-CD28 antibody |
|
STJ119563 |
St John's Laboratory |
100 µl |
EUR 332.4 |
|
Description: The protein encoded by this gene is essential for T-cell proliferation and survival, cytokine production, and T-helper type-2 development. Several alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
Anti-CD28 antibody |
|
STJ96609 |
St John's Laboratory |
200 µl |
EUR 236.4 |
|
Description: Rabbit polyclonal to CD28. |
 Lentivirus) Anti-h HLA-A2-ScFv- CD28-CD3ζ (No Select) Lentivirus |
|
LVP1668 |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 553 |
|
Description: Anti-h HLA-A2 CAR Lentivirus with human CD28 stimulatory domain, does not contain any antibiotic selection. |
 Lentivirus) Anti-h HLA-A2-ScFv- CD28-CD3ζ (GFP-Puro) Lentivirus |
|
LVP1670 |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 553 |
|
Description: Anti-h HLA-A2 CAR Lentivirus with human CD28 stimulatory domain, containing GFP-Puromycin dual selection. |
 Goat anti-CD28 Antibody |
|
MBS422554-01mg |
MyBiosource |
0.1mg |
EUR 400 |
Goat anti-CD28 Antibody |
|
MBS422554-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1660 |
 Mouse anti-CD28 Antibody |
|
DL99412A-100ul |
DL Develop |
100 ul |
EUR 299 |
|
|
|
Description: T-cell-specific surface glycoprotein CD28; TP44; CD28 |
Mouse anti-CD28 Antibody |
|
DL99412A-50ul |
DL Develop |
50 ul |
EUR 210 |
|
|
|
Description: T-cell-specific surface glycoprotein CD28; TP44; CD28 |
 Anti-CD28 Agonist Antibody |
|
100182-1 |
BPS Bioscience |
50 µg |
EUR 335 |
|
Description: Recombinant monoclonal antibody recognizing human CD28. This antibody binds to CD28 on T cells and promotes T cell response. Not tested in other species. This antibody crosslinked with FcGR2B is useful for activation of CD27 costimulatory pathway in T cells. |
Anti-CD28 Agonist Antibody |
|
100182-2 |
BPS Bioscience |
100 µg |
EUR 460 |
|
Description: Recombinant monoclonal antibody recognizing human CD28. This antibody binds to CD28 on T cells and promotes T cell response. Not tested in other species. |
 Anti-CD300f CD300LF Antibody |
|
A07913 |
BosterBio |
100ul |
EUR 399 |
|
|
|
Description: Boster Bio Anti-CD300f CD300LF Antibody catalog # A07913. Tested in IHC, WB applications. This antibody reacts with Human. |
 Anti-CD163b CD163L1 Antibody |
|
A09845 |
BosterBio |
100ul |
EUR 399 |
|
|
|
Description: Boster Bio Anti-CD163b CD163L1 Antibody catalog # A09845. Tested in IHC, WB applications. This antibody reacts with Human. |
 Anti-CD109 antigen CD109 Antibody |
|
A03248 |
BosterBio |
100ul |
EUR 380 |
|
|
|
Description: Boster Bio Anti-CD109 antigen CD109 Antibody catalog # A03248. Tested in ELISA, IHC applications. This antibody reacts with Human. |
 Anti-CD177 antigen CD177 Antibody |
|
A03958 |
BosterBio |
100ul |
EUR 399 |
|
|
|
Description: Boster Bio Anti-CD177 antigen CD177 Antibody catalog # A03958. Tested in IHC, WB applications. This antibody reacts with Human. |
 Anti-CD160 antigen CD160 Antibody |
|
A06168-2 |
BosterBio |
100ul |
EUR 380 |
|
|
|
Description: Boster Bio Anti-CD160 antigen CD160 Antibody catalog # A06168-2. Tested in ELISA, IHC, WB applications. This antibody reacts with Human. |
 Anti-CD320 antigen CD320 Antibody |
|
A06409 |
BosterBio |
100ul |
EUR 380 |
|
|
|
Description: Boster Bio Anti-CD320 antigen CD320 Antibody catalog # A06409. Tested in ELISA, WB applications. This antibody reacts with Human, Mouse, Rat. |
 Anti-CD16/CD32 [2.4G2] |
|
MBS488077-02mg |
MyBiosource |
0.2mg |
EUR 520 |
Anti-CD16/CD32 [2.4G2] |
|
MBS488077-5x02mg |
MyBiosource |
5x0.2mg |
EUR 2160 |
Anti-CD16/CD32 [2.4G2] |
|
MBS488078-02mg |
MyBiosource |
0.2mg |
EUR 520 |
Anti-CD16/CD32 [2.4G2] |
|
MBS488078-5x02mg |
MyBiosource |
5x0.2mg |
EUR 2160 |
) Anti-CD30 / TNFRSF8 Antibody (CD30/412) |
|
A1484-100 |
Biovision |
each |
EUR 574.8 |
 Anti-CD28 [15E8], Mouse IgG1 |
|
MBS488979-02mg |
MyBiosource |
0.2mg |
EUR 520 |
Anti-CD28 [15E8], Mouse IgG1 |
|
MBS488979-5x02mg |
MyBiosource |
5x0.2mg |
EUR 2160 |
 Anti-CD28 [15E8], Rabbit IgG |
|
MBS488980-02mg |
MyBiosource |
0.2mg |
EUR 520 |
Anti-CD28 [15E8], Rabbit IgG |
|
MBS488980-5x02mg |
MyBiosource |
5x0.2mg |
EUR 2160 |
 Antibody) Goat anti-Cd28 (mouse) Antibody |
|
MBS422610-01mg |
MyBiosource |
0.1mg |
EUR 400 |
Goat anti-Cd28 (mouse) Antibody |
|
MBS422610-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1660 |
) Anti-CD22 CAR Lentivirus (Clone m971 ScFv-CD8-4-1BB-CD3ζ) |
|
78608 |
BPS Bioscience |
50 µl |
EUR 1095 |
|
Description: The anti-CD22 CAR lentiviruses are replication incompetent, HIV-based, VSV-G-pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses transduce the ScFv (single-chain variable fragment) of anti-CD22 (clone m971) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains (below). |
 Anti-CD28 Antibody Picoband™ |
|
A00065-3 |
BosterBio |
10ug |
EUR 154 |
|
|
|
Description: Western blot, 0.25-0.5 μg/ml, Human;_x000D_Flow Cytometry, 1-3 μg/1x106 cells, Human;_x000D_Direct ELISA, 0.1-0.5 μg/ml, Human |
 Anti-CD300f/CD300LF Antibody, Rabbit Polyclonal |
|
MBS8101167-01mL |
MyBiosource |
0.1mL |
EUR 300 |
Anti-CD300f/CD300LF Antibody, Rabbit Polyclonal |
|
MBS8101167-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1200 |
Anti-CD300f/CD300LF Antibody, Rabbit Polyclonal |
|
MBS8101588-01mL |
MyBiosource |
0.1mL |
EUR 300 |
Anti-CD300f/CD300LF Antibody, Rabbit Polyclonal |
|
MBS8101588-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1200 |
 Antibody) Rabbit anti-CD28 (pY218) Antibody |
|
DL90184A-100ul |
DL Develop |
100 ul |
EUR 299 |
|
|
|
Description: T-cell-specific surface glycoprotein CD28; TP44; CD28 |
Rabbit anti-CD28 (pY218) Antibody |
|
DL90184A-50ul |
DL Develop |
50 ul |
EUR 209.3 |
|
|
|
Description: T-cell-specific surface glycoprotein CD28; TP44; CD28 |
Rabbit anti-CD28 (pY218) Antibody |
|
YLD1497-100ul |
Shanghai YL Biotech |
100 ul |
EUR 320 |
|
|
|
Description: Rabbit polyclonal antibody to CD28 (pY218) |
Rabbit anti-CD28 (pY218) Antibody |
|
YLD1497-50ul |
Shanghai YL Biotech |
50 ul |
EUR 200 |
|
|
|
Description: Rabbit polyclonal antibody to CD28 (pY218) |
 Anti-CD16/CD32 Antibody |
|
E38A8954 |
EnoGene |
100ug/100ul |
EUR 225 |
|
Description: Available in various conjugation types. |
 Anti-CD16+CD32 antibody |
|
MO16A(V100) |
ImmunoStep |
100 ug |
EUR 60 |
Anti-CD16+CD32 antibody |
|
MO16A(V25) |
ImmunoStep |
25 ug |
EUR 60 |
Anti-CD16+CD32 antibody |
|
MO16B(V100) |
ImmunoStep |
100 ug |
EUR 60 |
Anti-CD16+CD32 antibody |
|
MO16B(V25) |
ImmunoStep |
25 ug |
EUR 60 |
Anti-CD16+CD32 antibody |
|
MO16CFB(V100) |
ImmunoStep |
100 ug |
EUR 60 |
Anti-CD16+CD32 antibody |
|
MO16CFB(V25) |
ImmunoStep |
25 ug |
EUR 60 |
Anti-CD16+CD32 antibody |
|
MO16F(V100) |
ImmunoStep |
100 ug |
EUR 60 |
Anti-CD16+CD32 antibody |
|
MO16F(V25) |
ImmunoStep |
25 ug |
EUR 60 |
Anti-CD16+CD32 antibody |
|
MO16F(V500) |
ImmunoStep |
500 ug |
EUR 60 |
Anti-CD16+CD32 antibody |
|
MO16PE(V100) |
ImmunoStep |
100 ug |
EUR 60 |
Anti-CD16+CD32 antibody |
|
MO16PE(V25) |
ImmunoStep |
25 ug |
EUR 60 |
Anti-CD16+CD32 antibody |
|
MO16PP(V100) |
ImmunoStep |
100 ug |
EUR 60 |
Anti-CD16+CD32 antibody |
|
MO16PP(V25) |
ImmunoStep |
25 ug |
EUR 60 |
Anti-CD16+CD32 antibody |
|
MO16PP5.5(V100) |
ImmunoStep |
100 ug |
EUR 60 |
Anti-CD16+CD32 antibody |
|
MO16PP5.5(V25) |
ImmunoStep |
25 ug |
EUR 60 |
Anti-CD16+CD32 antibody |
|
MO16PU(V100) |
ImmunoStep |
100 ug |
EUR 60 |
Anti-CD16+CD32 antibody |
|
MO16PU(V500) |
ImmunoStep |
500 ug |
EUR 60 |
 Phospho Antibody) Anti-CD28 (pY218) Phospho Antibody |
|
MBS820419-003mL |
MyBiosource |
0.03mL |
EUR 195 |
Anti-CD28 (pY218) Phospho Antibody |
|
MBS820419-01mL |
MyBiosource |
0.1mL |
EUR 285 |
Anti-CD28 (pY218) Phospho Antibody |
|
MBS820419-02mL |
MyBiosource |
0.2mL |
EUR 390 |
Anti-CD28 (pY218) Phospho Antibody |
|
MBS820419-5x02mL |
MyBiosource |
5x0.2mL |
EUR 1660 |
 Anti-CD70/Cd27L Antibody |
|
A02853 |
BosterBio |
100ul |
EUR 360 |
|
|
|
Description: Boster Bio Anti-CD70/Cd27L Antibody (Catalog # A02853). Tested in WB applications. This antibody reacts with Human. |
 Rat anti-CD16/CD32 Antibody |
|
DL99452A-100ul |
DL Develop |
100 ul |
EUR 299 |
|
|
|
Description: CD32; FCG2; IGFR2; Low affinity immunoglobulin gamma Fc region receptor II-b; IgG Fc receptor II-b; CDw32; Fc-gamma RII-b; Fc-gamma-RIIb; FcRII-b; CD32 |
Rat anti-CD16/CD32 Antibody |
|
DL99452A-50ul |
DL Develop |
50 ul |
EUR 210 |
|
|
|
Description: CD32; FCG2; IGFR2; Low affinity immunoglobulin gamma Fc region receptor II-b; IgG Fc receptor II-b; CDw32; Fc-gamma RII-b; Fc-gamma-RIIb; FcRII-b; CD32 |
 Syrian Hamster anti-CD28 Antibody |
|
DL99429A-100ul |
DL Develop |
100 ul |
EUR 299 |
|
|
|
Description: T-cell-specific surface glycoprotein CD28; TP44; CD28 |
Syrian Hamster anti-CD28 Antibody |
|
DL99429A-50ul |
DL Develop |
50 ul |
EUR 210 |
|
|
|
Description: T-cell-specific surface glycoprotein CD28; TP44; CD28 |
) Anti-CD28 Reference Antibody (FR104) |
|
E24CHA679 |
EnoGene |
100 μg |
EUR 225 |
|
Description: Available in various conjugation types. |
 Anti-CD28 Antibody, Mouse Monoclonal |
|
MBS8105379-01mL |
MyBiosource |
0.1mL |
EUR 300 |
Anti-CD28 Antibody, Mouse Monoclonal |
|
MBS8105379-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1200 |
Anti-CD28 Antibody, Mouse Monoclonal |
|
MBS8112916-01mL |
MyBiosource |
0.1mL |
EUR 300 |
Anti-CD28 Antibody, Mouse Monoclonal |
|
MBS8112916-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1200 |
) Recombinant Anti-CD33 x Anti-CD16 x CD123 Trispecific Antibody (Single-chain Triplebody) |
|
SCTB-104 |
Creative Biolabs |
200μg |
Ask for price |
|
Description: A trispecific antibody that is expressed as a single chain with three scFv units, two distal binding sites for CD33 and CD123, a central site for CD16. This BsAb can retarget NK cells to tumor cells. It is designed for the research of Acute myeloid leukemia (AML) therapy. |
) Anti-CD28 Agonist Antibody (Humanized) |
|
100186-1 |
BPS Bioscience |
50 µg |
EUR 345 |
|
Description: Recombinant monoclonal antibody recognizing human CD28. This antibody binds to CD28 on T cells and promotes T cell response. Not tested in other species. This antibody crosslinked with FcGR2B is useful for activation of CD27 costimulatory pathway in T cells. This antibody has been humanized to reduce immunogenicity and improve the therapeutic half-life. |
Anti-CD28 Agonist Antibody (Humanized) |
|
100186-2 |
BPS Bioscience |
100 µg |
EUR 475 |
|
Description: Recombinant monoclonal antibody recognizing human CD28. This antibody binds to CD28 on T cells and promotes T cell response. Not tested in other species. This antibody has been humanized to reduce immunogenicity and improve the therapeutic half-life. |
 Anti-CD28 Antibody, Rabbit Polyclonal |
|
MBS8110990-01mL |
MyBiosource |
0.1mL |
EUR 300 |
Anti-CD28 Antibody, Rabbit Polyclonal |
|
MBS8110990-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1200 |
Anti-CD28 Antibody, Rabbit Polyclonal |
|
MBS8110991-01mL |
MyBiosource |
0.1mL |
EUR 300 |
Anti-CD28 Antibody, Rabbit Polyclonal |
|
MBS8110991-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1200 |
Anti-CD28 Antibody, Rabbit Polyclonal |
|
MBS8110992-01mL |
MyBiosource |
0.1mL |
EUR 300 |
Anti-CD28 Antibody, Rabbit Polyclonal |
|
MBS8110992-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1200 |
Anti-CD28 Antibody, Rabbit Polyclonal |
|
MBS8105383-01mL |
MyBiosource |
0.1mL |
EUR 300 |
Anti-CD28 Antibody, Rabbit Polyclonal |
|
MBS8105383-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1200 |
Anti-CD28 Antibody, Rabbit Polyclonal |
|
MBS8105384-01mL |
MyBiosource |
0.1mL |
EUR 300 |
Anti-CD28 Antibody, Rabbit Polyclonal |
|
MBS8105384-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1200 |
Anti-CD28 Antibody, Rabbit Polyclonal |
|
MBS8112917-01mL |
MyBiosource |
0.1mL |
EUR 300 |
Anti-CD28 Antibody, Rabbit Polyclonal |
|
MBS8112917-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1200 |
Utility of the SA in erbium-doped fiber laser and steady passive Q-switched operation with a most pulse power of 430.47 nJ is realized. By adjusting the polarization state and pump energy, high-power mode-locked pulses are generated with a pulse period and output energy of 199 fs and 54.13 mW, respectively. Additional, bound-state soliton pulses are obtained with a pulse width of 312 fs and soliton interval of 1.26 ps for the primary time primarily based on MXene supplies. Furthermore, by utility of the SA in ytterbium-doped fiber lasers, a steady dissipative soliton mode-locked pulse is obtained with a pulse width of 23 ps. These outcomes point out that the DF-based buried Mo2C as a novel SA offers a dependable methodology for all-fiber and multifunctional high-power ultrafast laser.
